NASDAQ : CTOR
Citius Oncology, Inc. — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 0.5295 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 56.00M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
Details
| Name | Citius Oncology, Inc. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Founded | 2021 |
| Ceo | Leonard Mazur |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| Isin | US17331Y1091 |
| Cusip | 17331Y109 |
| Cik | 1851484 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Leonard L. Mazur | Chief Executive Officer, President and Executive Chairman |
| Myron Z. Holubiak | Secretary and Executive Vice Chairman |
| Dr. Myron S. Czuczman M.D. | Executive Vice President and Chief Medical Officer |
| Jaime Bartushak | Chief Financial Officer and Treasurer |
Contact
| Address | 11 Commerce Drive, First Floor, Cranford, New Jersey 07016, United States |
| Phone | 908 967 6677 |
| Website | https://citiusonc.com/overview/default.aspx |